COMMUNIQUÉS West-GlobeNewswire

Judo Bio’s Megalin-STRIKERs Achieve First Demonstration of Functional Pharmacodynamic Effects from Kidney Selective Gene Silencing in Non-Human Primates
08/11/2025
Data presented at Kidney Week 2025 showed single subcutaneous administration of megalin-STRIKERs resulted in increased excretion of disease-related solute levels lasting for at least 2 months Dr. Ravi Thadhani, [...]
Jade Biosciences Presents New Data Demonstrating a Favorable Preclinical Safety Profile of JADE101 and a Translational Analysis of APRIL Mediated Biomarker Responses at the American Society of Nephrology Kidney Week 2025
08/11/2025
SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in- [...]
Phase 2 Trials Demonstrating Antithrombotic Effect of Two Novel Regeneron Factor XI Antibodies Presented at American Heart Association Scientific Sessions and Published in The Lancet
08/11/2025
Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results consistent with [...]
Acoramidis Significantly Reduces All-cause Mortality in the Overall ATTR-CM Variant and V142I (V122I) Populations
08/11/2025
- Simultaneously published in JAMA Cardiology along with moderated posters at AHA, acoramidis demonstrated: 59% risk reduction in ACM in the ATTR-CM variant population at Month 42 (p=0.032) compared to patients [...]
CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering
08/11/2025
-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in circulating ANGPTL3 [...]
MemoMaster Unveiled: How This Memo Master Cutting-Edge Brain Support Supplement Is Redefining Focus and Memory Health for the Digital Era
08/11/2025
Boost memory, focus & mental clarity with MemoMaster – a clinically inspired brain supplement for sharper thinking, sustained energy & long-term brain health. New York, Nov. 08, 2025 (GLOBE NEWSWIRE) -- [...]
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
08/11/2025
Bagsværd, Denmark, 8 November 2025 – Novo Nordisk today confirms that it does not intend to make an increased offer to acquire Metsera. On 30 October 2025, Novo Nordisk announced the submission of an unsolicited [...]
Fangzhou Awarded “Golden Bull Award” for Leadership in AI-Powered Chronic Disease Management
08/11/2025
XIAMEN, China, Nov. 08, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. (“Fangzhou” or the “Company”) (HKEX: 06086), a leading provider of AI-driven Internet healthcare solutions, was recognized with the “Social Responsibility [...]
Smile Spa Camarillo Officially Opens its Doors, Offering State-of-the-Art Dental Care in Ventura County
08/11/2025
Camarillo, CA, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Smile Spa Camarillo, a modern dental office led by Dr. Joelle Abed Elahad and Dr. Shawn Nguyen, is proud to announce that it has officially opened its doors at 400 W [...]
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy
08/11/2025
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% reduction from [...]
Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025
08/11/2025
– Late-breaking presentation of Explore-CKD trial at ASN Kidney Week – – Pivotal Phase 3 Launch-HTN trial featured in the “Best of JAMA and NEJM” session - RADNOR, Pa., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Mineralys [...]
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
08/11/2025
In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by tardive dyskinesia (TD) while taking AUSTEDO or AUSTEDO XR Most (85%) [...]
Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
07/11/2025
New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting Following the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, [...]
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
07/11/2025
Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure WOBURN, Mass., Nov. 07, 2025 (GLOBE [...]
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07/11/2025
CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with [...]
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
07/11/2025
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Nov. 07, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of [...]
Cannabix Technologies announces Non-Brokered LIFE Private Placement
07/11/2025
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (the “Company or [...]
Cellectis Reports Third Quarter 2025 Financial Results and Provides Business Update
07/11/2025
Presented data underscore the potential of lasme-cel (UCART22) and eti-cel (UCART20x22) to improve outcomes in r/r B-ALL and r/r NHL: Lasme-cel in r/r B-ALL (BALLI-01) ORR of 68% with lasme-cel Process 2 (n=22), 83% at [...]
Cellectis publie ses résultats financiers du troisième trimestre 2025 et une mise à jour de ses activités
07/11/2025
Les données présentées confirment le potentiel de lasmé-cel (UCART22) et d’éti-cel (UCART20x22) pour améliorer les résultats cliniques dans la LAL-B et le LNH en rechute ou réfractaire : Lasmé-cel dans la LAL-B en [...]

Pages